Study of Telatinib in Colorectal Cancer Patients
Author Information
Author(s): Klaus Mross, Annette Frost, Max E Scheulen, Jürgen Krauss, Dirk Strumberg, Beate Schultheiss, Ulrike Fasol, Martin Büchert, Jörn Krätzschmer, Heinz Delesen, Prabhu Rajagopalan, Olaf Christensen
Primary Institution: Tumor Biology Center at the Albert-Ludwigs-University Freiburg, Germany
Hypothesis
Is telatinib effective and safe for patients with refractory colorectal cancer?
Conclusion
Telatinib treatment was well tolerated, but showed limited antitumor activity in heavily pretreated colorectal cancer patients.
Supporting Evidence
- Hypertension was the most common side effect, affecting 28% of patients.
- 41% of patients experienced some tumor shrinkage during treatment.
- No partial remission was observed according to RECIST criteria.
Takeaway
This study tested a new drug called telatinib on patients with colon cancer. While the drug was safe to use, it didn't work very well to shrink the tumors.
Methodology
A multicenter phase I dose-escalation study with 39 patients receiving telatinib at doses of ≥ 600 mg twice daily.
Potential Biases
Potential bias due to the non-randomized design and the small sample size.
Limitations
The study involved a small sample size and was limited to heavily pretreated patients.
Participant Demographics
39 Caucasian patients with refractory colorectal cancer, predominantly male (51%) with a mean age of 60.2 years.
Statistical Information
P-Value
0.0026
Statistical Significance
p=0.0026
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website